COMPANY PROFILE

MBD

Explore full profile

Specializing in precision medicine and new drug development through 3D cell culture platform technology

South KoreaFounded 2015Biotech & Life Sciences

Valuation $100–500M Latest valuation · 2025

Total funding $10–50M Disclosed equity funding

At a glance

Status: Operational
Founded: 2015
Headquarters: South Korea
Open positions: None listed
Dealroom signal: 23.7/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Precision Medicine, Biotech and Pharma, Hard Tech, DT and LS, science-based
Technology: 3D Technology
Business model: Manufacturing
Client focus: b2b
Investment activity: 1 company, latest Nov 2025
Capital deployed: $0
Preferred round: LATE VC
Links: Website

Press, funding announcements and product moves mentioning MBD.

2 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES C✓Equity / VC	Aug 2025	$32M	$127M	Undisclosed	↗
SERIES B✓Equity / VC	Mar 2021	$9.6M	$39M	Hana Financial Investment · Daedeok Venture Partners · BSK Investment · Shinhan Venture Investment	—

MBD website traffic

Latest recorded traffic for MBD is 1.7K monthly website visits, down 29.2% over the last three months.

Latest monthly visits1.7K 3-month web change-29.2%

Monthly website visitsDec 2020–Jul 2026

Summary metrics are public; monthly history is available with a demoCompare with peers →

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
NTNucleome TherapeuticsDecoding the dark matter of the human genome to discover first-in-class precision medicine	Oxford, United Kingdom	Operational	53	$47M	$160M
VIVitroScanDedicated to delivering predictive diagnostic testing to support better informed treatment decisions for cancer patients	Leiden, Netherlands	Operational
PBPhagoMed BiopharmaDevelops endolysins and phage as therapeutics	Vienna, Austria	Acquired
NONodus OncologyNext-generation precision medicines targeting DNA damage response	Macclesfield, United Kingdom	Operational
SBShanghai Junyuan BiotechnologyImplements a technological innovation-driven development strategy and focuses on the precision medical molecular diagnosis track	China	Operational
TGTongshu GeneA high-tech enterprise that focuses on scientific and technological innovation and focuses on precise molecular diagnosis of tumors	China	Operational
STSama TherapeuticsPrecision Neuropsychiatry AI/ML platform to accelerate psychedelic-inspired R&D	Cambridge, United States	Operational
ETENSEM TherapeuticsBiotechnology company focusing on high value and difficult-to-drug oncology targets	Medford, United States	Operational